Page last updated: 2024-12-07

alpha-hydroxyisocaproic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-hydroxyisocaproic acid: alpha-hydroxy analog of leucine; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-hydroxy-4-methylvaleric acid : A valeric acid derivative having a hydroxy substituent at the 2-position and a methyl substituent at the 4-position; an alpha-hydroxy analogue of leucine. A bacterial metabolite, it has also been isolated from amniotic fluid, was found in a patient with dihydrolipoyl dehydrogenase deficiency and is present in the urine of patients with short bowel syndrome. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92779
CHEMBL ID3247392
CHEBI ID59783
SCHEMBL ID185354
MeSH IDM0071873

Synonyms (78)

Synonym
2-hydroxy-4-methyl-pentanoic acid
2-hydroxyisocaproic acid, 99%
leucic acid
inchi=1/c6h12o3/c1-4(2)3-5(7)6(8)9/h4-5,7h,3h2,1-2h3,(h,8,9)
lvrftazaxqpqhi-uhfffaoysa-
alpha-hydroxyisocaproic acid
2-hydroxyisohexanoic acid
CHEBI:59783 ,
498-36-2
dl-2-hydroxy-4-methylvaleric acid
pentanoic acid, 2-hydroxy-4-methyl-
2-hydroxy-4-methylvaleric acid
2-hydroxyisocaproic acid
2-hydroxy-4-methylpentanoic acid
BMSE000338
dl-leucic acid
FT-0695018
FT-0693263
STK895083
L0104
LMFA01050381
leucinic acid
AKOS005614031
A827869
8rn4nsx3ty ,
einecs 207-860-8
dl-2-hydroxyisocaproic acid
einecs 233-677-8
(+-)-leucinic acid
dl-alpha-hydroxyisocaproic acid
unii-8rn4nsx3ty
FT-0625479
FT-0627928
10303-64-7
CHEMBL3247392
hica
SCHEMBL185354
pentanoic acid, 2-hydroxy-4-methyl-, (s)-
2-hydroxy-4-methylpentanoic acid #
alpha hydroxyisocaproic acid
leucic acid, (+/-)-
(+/-)-2-hydroxyisohexanoic acid
dl-.alpha.-hydroxyisocaproic acid
dl-2-hydroxy-4-methylpentanoic acid
(+/-)-leucic acid
leucic acid, dl-
(+/-)-2-hydroxyisocaproic acid
(+/-)-leucinic acid
mfcd00004246
AS-60347
dl-2-hydroxyisocaproate
a-hydroxyisocaproic acid
dl-a-hydroxyisocaproic acid
dl-leucate
dl-2-hydroxy-4-methylpentanoate
2-hydroxy-4-methyl-valeric acid
dl-alpha-hydroxyisocaproate
a-hydroxy-iso-caproate
2-hydroxyisohexanoate
a-hydroxy-iso-caproic acid
leucate
alpha-hydroxy-iso-caproate
2-hydroxy-4-methyl-valerate
dl-a-hydroxyisocaproate
alpha-hydroxy-iso-caproic acid
a-hydroxyisocaproate
DTXSID80862047
F8882-4328
Q17037730
AMY22161
EN300-146687
D87748
SY066744
2-hydroxy-4-methylpentanoicacid
SB44624
SY066416
HY-30216A
CS-0135968

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"5, 5, 10, 20, and 40 mg/mL) for 24 hours, and a dose-response curve was generated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay."( Cytotoxicity and Genotoxicity of a New Intracanal Medicament, 2-hydroxyisocaproic Acid-An In Vitro Study.
Alhabeil, J; Askar, M; Pande, Y; Paurazas, S; Selis, D; Smoczer, C; Wheater, M, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-hydroxy fatty acidAny fatty acid with a hydroxy functional group in the alpha- or 2-position.
branched-chain fatty acidAny fatty acid in which the parent hydrocarbon chain has one or more alkyl substituents; a common component in animal and bacterial lipids. The fatty acyl chain is usually saturated and the substituent a methyl group; however, unsaturated BCFAs are found in marine animals, and branches other than methyl are found in microbial lipids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1130306Inhibition of glycolic acid oxidase (unknown origin) assessed as enzyme-mediated reduction of NaDCIP by sodium glycolate after 1 to 3 mins by spectrophotometer analysis1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Quantitative structure-activity relationships involving the inhibition of glycolic acid oxidase by derivatives of glycolic and glyoxylic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (28.57)18.7374
1990's1 (2.86)18.2507
2000's0 (0.00)29.6817
2010's19 (54.29)24.3611
2020's5 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.97 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index29.56 (26.88)
Search Engine Supply Index2.73 (0.95)

This Compound (23.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (8.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (5.71%)4.05%
Observational0 (0.00%)0.25%
Other30 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]